EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

JS Smolen, R Landewé, J Bijlsma… - Annals of the …, 2017 - ard.bmj.com
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

Infection risk and safety of corticosteroid use

J Youssef, SA Novosad… - … diseases clinics of North …, 2015 - pmc.ncbi.nlm.nih.gov
Corticosteroids are frequently used to treat rheumatic diseases. Their use comes with a
number of well-established risks including osteoporosis, avascular necrosis, glaucoma, and …

2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis

L Fraenkel, JM Bathon, BR England… - Arthritis & …, 2021 - Wiley Online Library
Objective To develop updated guidelines for the pharmacologic management of rheumatoid
arthritis. Methods We developed clinically relevant population, intervention, comparator, and …

2016 update of the EULAR recommendations for the management of early arthritis

B Combe, R Landewe, CI Daien, C Hua… - Annals of the …, 2017 - ard.bmj.com
Objectives Since the 2007 recommendations for the management of early arthritis have
been presented, considerable research has been published in the field of early arthritis …

Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study

MD George, JF Baker, K Winthrop, JY Hsu… - Annals of internal …, 2020 - acpjournals.org
Background: Low-dose glucocorticoids are frequently used for the management of
rheumatoid arthritis (RA) and other chronic conditions, but the safety of long-term use …

The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment

J Listing, K Gerhold, A Zink - Rheumatology, 2013 - academic.oup.com
RA is known to be associated with an increased risk of serious infection. Even more than 50
years ago, observational studies showed a greater than 2-fold increased risk of serious …

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints …

C Strehl, JWJ Bijlsma, M De Wit, M Boers… - Annals of the …, 2016 - ard.bmj.com
There is convincing evidence for the known and unambiguously accepted beneficial effects
of glucocorticoids at low dosages. However, the implementation of existing …

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti …

X Michelena, H Borrell, M Lopez-Corbeto… - Seminars in arthritis and …, 2020 - Elsevier
Objectives To investigate the incidence of COVID-19 in a cohort of adult and paediatric
patients with rheumatic diseases receiving targeted biologic and synthetic disease …

Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?

R Pofi, G Caratti, DW Ray, JW Tomlinson - Endocrine Reviews, 2023 - academic.oup.com
It is estimated that 2% to 3% of the population are currently prescribed systemic or topical
glucocorticoid treatment. The potent anti-inflammatory action of glucocorticoids to deliver …

[HTML][HTML] French health insurance databases: what interest for medical research?

G Moulis, M Lapeyre-Mestre, A Palmaro… - La Revue de médecine …, 2015 - Elsevier
French health insurance databases are organized since 2003 into a huge digital data
warehouse, the Système national d'information inter-régime de l'assurance maladie (SNIIR …